This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Management

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Early intervention is not required in patients with asymptomatic myeloma (1).

  • only requires close monitoring under the supervision of a consultant haematologist
  • entry into clinical trials (if available) should be considered in this group
  • chemotherapy may be beneficial in patients with a rising M-protein concentration in the absence of ROTI (1)

The overall risk of progression to symptomatic myeloma during the first 5 years is around 10% per year but declines in subsequent years.

Monitoring of asymptomatic myeloma patients include the following:

  • regular (typically 3 monthly) clinical assessment for the emergence of ROTI
  • measurement of serum and urinary M-protein (and SFLC when indicated) (1)

A repeat of bone marrow examination and skeletal imaging should be considered before starting therapy in these patients (1).

The ability of immunomodulatory drugs to delay the progression from asymptomatic to symptomatic myeloma is under investigation (2).

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.